Miriam Segale
Milan, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Circulating extracellular vesicles from early-stage lung cancer patients trigger endothelial activation to drive pre-metastatic niche formation through synergistic miR-29a and C4A signaling.
Journal: Journal of experimental & clinical cancer research : CR
Published: February 03, 2026
Clinical Value of Combining Molecular and Immune Blood Tests to Safely Reduce False Positives in Low-Dose Computed Tomography Lung Cancer Screening.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: November 24, 2025
Upfront blood microRNA test in LDCT-reluctant individuals: insights from the biomild trial.
Journal: Journal of experimental & clinical cancer research : CR
Published: April 04, 2025
Blood microRNA testing in participants with suspicious low-dose CT findings: follow-up of the BioMILD lung cancer screening trial.
Journal: The Lancet regional health. Europe
Published: June 19, 2024
Development of a Molecular Blood-Based Immune Signature Classifier as Biomarker for Risks Assessment in Lung Cancer Screening.
Journal: Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
Published: June 15, 2022
Circulating extracellular vesicles from individuals at high-risk of lung cancer induce pro-tumorigenic conversion of stromal cells through transfer of miR-126 and miR-320.
Journal: Journal of experimental & clinical cancer research : CR
Published: March 31, 2021
Cotargeting of miR-126-3p and miR-221-3p inhibits PIK3R2 and PTEN, reducing lung cancer growth and metastasis by blocking AKT and CXCR4 signalling.
Journal: Molecular oncology
Published: February 04, 2021
Showing 1-10 of 10
Last Updated: 09/26/2026